During a platform presentation at the recent 21st Annual Meeting of the Northeast ALS Consortium, as well as in an abstract published in Muscle & Nerve, the researchers reported no moderate or severe adverse events, and identified no abnormalities or general trends in any safety assessments in patients given four dose levels of prosetin, from 0.03 to 0.24 mg/kg. Plasma levels of prosetin increased in a predictable manner.